Oracle shares slip as analysts flag AI capex and equity raise concerns

Oracle Corporation's stock fell 4.8% on Monday, trading as low as $174.40 and closing at $175.38, with trading volume down 16% from its average. The decline followed mixed analyst sentiment after the company reported record quarterly revenue and strong demand for AI infrastructure, while also announcing an aggressive capital‑expenditure plan and a $20 billion equity raise that raised worries about margin pressure and dilution.

Rockefeller Capital Management trimmed its Oracle position by 29,164 shares, a 4.4% reduction, leaving it with 628,097 shares valued at roughly $122.4 million. Other institutional investors such as Bank of New Hampshire, Lane Brothers & Co., Farmers National Bank, Nalls Sherbakoff Group and Meadowbrook Advisors adjusted or opened positions, collectively increasing institutional ownership to about 42.44% of the stock. Meanwhile, Baystate Health expanded its strategic partnership with Oracle Health, deploying more AI and electronic health‑record tools across its facilities, adding a positive note to the company's healthcare software outlook.